Page last updated: 2024-12-05

4-chlorobiphenyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Chlorobiphenyl (4-CB) is a persistent organic pollutant (POP) that belongs to the family of polychlorinated biphenyls (PCBs). It is a colorless, odorless, and viscous liquid at room temperature. 4-CB is commonly found in the environment as a result of industrial emissions, waste disposal, and the breakdown of other PCBs. It has been shown to have a variety of adverse effects on human health and the environment. For instance, 4-CB is a known endocrine disruptor, which means it can interfere with the body's hormonal system. It has also been linked to developmental problems, reproductive toxicity, and cancer in animals. 4-CB is particularly important to study due to its persistence in the environment and its potential to bioaccumulate in living organisms. Its presence in the food chain can pose a significant threat to human and wildlife health. Research on 4-CB focuses on understanding its environmental fate, toxicity, and potential for remediation. This includes studies on its chemical stability, breakdown pathways, bioaccumulation in various organisms, and the development of methods for removing it from contaminated environments. 4-CB is an example of a compound that highlights the importance of responsible industrial practices and environmental protection to mitigate the risks posed by persistent pollutants.'

4-chlorobiphenyl : A monochlorobiphenyl carrying a chloro substituent at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16323
CHEMBL ID276334
CHEBI ID27757
SCHEMBL ID183912
MeSH IDM0049859

Synonyms (57)

Synonym
CHEBI:27757 ,
4-chlorbiphenyl
1,1'-biphenyl, 4-chloro-
biphenyl, 4-chloro-
wln: gr dr
p-chlorobiphenyl
4-chlorodiphenyl
4-chloro-1,1'-biphenyl
nsc-37066
p-chlorodiphenyl
nsc37066
AE-562/43287010
inchi=1/c12h9cl/c13-12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9
einecs 218-127-7
nsc 37066
ai3-00135
4-monochlorobiphenyl
C06584
4-chlorobiphenyl
4-monochloro-biphenyl
2051-62-9
1-chloro-4-phenyl benzene
AC-10360
CHEMBL276334 ,
4-chloro-biphenyl
bdbm50159271
4-chloro-1,1''-biphenyl
1-chloro-4-phenylbenzene
AKOS005254766
unii-qa22z3nglu
qa22z3nglu ,
ccris 9311
1-chloranyl-4-phenyl-benzene
A814632
FT-0617970
CX1304
pcb 3
chloro-1,1'-biphenyl, 4-
SCHEMBL183912
4-chlorophenylbenzene
dtxcid1020300
tox21_303788
cas-2051-62-9
dtxsid3040300 ,
NCGC00356978-01
W-107615
PS-8431
mfcd00013640
pcb no 3, analytical standard
pcb no. 3 10 microg/ml in isooctane
pcb no. 3
BBL103159
STL556969
51624-37-4
Q27103306
clc1=cc=c(c2=cc=cc=c2)c=c1
4-chlorobiphenyl-d5

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Polychlorinated biphenyls (PCBs) and their metabolites are environmental pollutants that are known to have adverse health effects."( Succinate dehydrogenase activity regulates PCB3-quinone-induced metabolic oxidative stress and toxicity in HaCaT human keratinocytes.
Buettner, GR; Domann, FE; Doskey, CM; Goswami, PC; Sarsour, EH; Wagner, BA; Xiao, W, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" Potent and specific inhibitors of the CYP2A6 enzyme can be used in the future to increase nicotine bioavailability and thus make oral nicotine administration feasible in smoking cessation therapy."( Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
Juvonen, RO; Poso, A; Rahnasto, M; Raunio, H; Wittekindt, C, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
" A dose-response curve for each of the suicide inhibitors was developed."( Inhibition of cytochromes P450 and the hydroxylation of 4-monochlorobiphenyl in whole poplar.
Lehmler, HJ; Schnoor, JL; Zhai, G, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monochlorobiphenylA chlorobiphenyl carrying a single chloro substituent at unspecified position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency70.97990.007215.758889.3584AID1224835
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)49.00000.00011.774010.0000AID241334
Cytochrome P450 2A6Homo sapiens (human)IC50 (µMol)149.98400.00443.889510.0000AID241172; AID420671
Cytochrome P450 2A5Mus musculus (house mouse)IC50 (µMol)15.50091.00004.20259.7051AID241174; AID420670
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID242975Ratio of IC50 for human CYP2A6 to that of mouse CYP2A5 was determined2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID241172Inhibitory concentration against human cytochrome P450 2A62005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID23673Partition coefficient (logP)2002Bioorganic & medicinal chemistry letters, Apr-08, Volume: 12, Issue:7
Novel estimation of lipophilic behaviour of polychlorinated biphenyls.
AID241334Inhibitory concentration against recombinant human cytochrome P450 1A22005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.
AID420671Inhibition of human CYP2A62009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques.
AID241174Inhibitory concentration against mouse cytochrome P450 2A52005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID420670Inhibition of mouse CYP2A52009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques.
AID600448Aqueous solubility of the compound in water2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (86)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (25.58)18.7374
1990's20 (23.26)18.2507
2000's24 (27.91)29.6817
2010's18 (20.93)24.3611
2020's2 (2.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.60 (24.57)
Research Supply Index4.51 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other89 (98.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]